Please login to the form below

Not currently logged in
Email:
Password:

Chris Molloy is new head of RSA

Life sciences executive search and interim management specialist RSA has appointed a new chief executive

RSA Chris MolloyChris Molloy, a non-executive director at RSA since 2009, joins RSA in a full-time capacity from IDBS, where he was VP, corporate development and marketing.

Molloy brings with him more than 20 years' experience in life sciences, spanning the pharmaceuticals, biotechnology and start-up sectors.

He started out with Glaxo, where he held a range of management, research, business change and scientific collaboration roles through the company's merger to become GlaxoSmithKline (GSK), before moving to Asia in 2004 as chief operating officer of emerging biotech firm MerLion Pharmaceuticals.

In addition to taking over as CEO at RSA, Molloy will retain his active scientific role in the pre-clinical development and licensing of new medicines for HIV with KFLP Biotech, a 'virtual' US R&D company.

“We are excited to have Chris on board as RSA's CEO. He will continue to preserve the special culture and feel of RSA whilst making us even more professional as an executive search and interim business,” said executive chairman Nick Stephens.

11th September 2013

From: Sales, Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics